{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T22:10:14Z","timestamp":1758579014603,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.transproceed.2022.10.063","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T18:03:13Z","timestamp":1672855393000},"page":"123-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is Polyomavirus-Associated Nephropathy More Common in Kidney Transplant Recipients Exposed to Valganciclovir? A Retrospective Single Center Analysis"],"prefix":"10.1016","volume":"55","author":[{"given":"Rachel","family":"Hellemans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2008-3662","authenticated-orcid":false,"given":"Andrea","family":"Bertels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Wijtvliet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristien","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Massart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristof","family":"Bergs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Matheeussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Abramowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2022.10.063_bib0001","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1097\/TP.0000000000001333","article-title":"BK polyomavirus and the transplanted kidney: immunopathology and therapeutic approaches","volume":"100","author":"Lamarche","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0002","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1097\/TP.0b013e3182921995","article-title":"Risk factors for BK virus infection in the era of therapeutic drug monitoring","volume":"95","author":"Borni-Duval","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0003","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/TP.0000000000000890","article-title":"Risk factors for bk polyoma virus treatment and association of treatment with kidney transplant failure: insights from a paired kidney analysis","volume":"100","author":"Thangaraju","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0004","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMoa020439","article-title":"Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients","volume":"347","author":"Hirsch","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0005","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/TP.0b013e31819cc383","article-title":"An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States","volume":"87","author":"Dharnidharka","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0006","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-6143.2012.04320.x","article-title":"Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study","volume":"13","author":"Hirsch","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0007","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/ajt.13541","article-title":"BK Polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12","volume":"16","author":"Hirsch","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0008","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.trre.2011.05.002","article-title":"The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen","volume":"26","author":"Suwelack","year":"2012","journal-title":"Transplant Rev"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0009","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0011","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/ctr.12151","article-title":"Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience","volume":"27","author":"Moscarelli","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0012","doi-asserted-by":"crossref","first-page":"270","DOI":"10.12998\/wjcc.v7.i3.270","article-title":"Incidence, risk factors, and outcome of BK polyomavirus infection after kidney transplantation","volume":"7","author":"Favi","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0013","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1111\/j.1600-6143.2005.01000.x","article-title":"Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia","volume":"5","author":"Bohl","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0014","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ajt.12110","article-title":"BK polyomavirus in solid organ transplantation","volume":"13","author":"Hirsch","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.tp.0000269616.21698.10","article-title":"Ureteral stents: a novel risk factor for polyomavirus nephropathy","volume":"84","author":"Thomas","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0016","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1111\/ajt.15598","article-title":"BK polyomavirus and valganciclovir: highly suspected association urgently calling for a new randomized trial","volume":"19","author":"Reischig","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0017","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1111\/ajt.15610","article-title":"Valganciclovir is not a risk factor of BK polyomavirus viremia","volume":"19","author":"Jehn","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0018","doi-asserted-by":"crossref","first-page":"e13467","DOI":"10.1111\/tid.13467","article-title":"A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high-risk patients and a pre-emptive strategy in intermediate-risk patients: combining the best of two options?","volume":"23","author":"Hellemans","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0019","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.15507","article-title":"Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy","volume":"19","author":"Reischig","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","article-title":"Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation","volume":"8","author":"Reischig","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0021","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.07020714","article-title":"Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation","volume":"10","author":"Reischig","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0022","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s12879-018-3493-y","article-title":"Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial","volume":"18","author":"Reischig","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0023","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1172\/JCI115217","article-title":"Inhibition of immune functions by antiviral drugs","volume":"87","author":"Heagy","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0024","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/infdis\/156.6.899","article-title":"Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses","volume":"156","author":"Bowden","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0025","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bbmt.2007.03.009","article-title":"Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis","volume":"13","author":"Battiwalla","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcv.2015.12.012","article-title":"In vitro studies of the impact of maribavir on CMV-specific cellular immune responses","volume":"75","author":"Stachel","year":"2016","journal-title":"J Clin Virol"},{"key":"10.1016\/j.transproceed.2022.10.063_bib0027","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3851\/IMP1879","article-title":"Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients","volume":"16","author":"Reischig","year":"2011","journal-title":"Antivir Ther"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134522007813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134522007813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:43:56Z","timestamp":1758577436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134522007813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0041134522007813"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2022.10.063","relation":{},"ISSN":["0041-1345"],"issn-type":[{"type":"print","value":"0041-1345"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is Polyomavirus-Associated Nephropathy More Common in Kidney Transplant Recipients Exposed to Valganciclovir? A Retrospective Single Center Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2022.10.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}